Navigation Links
Smartphone app reads blood oxygen levels to hospital standards, advances to global obstetrics tests
Date:3/9/2014

ment opportunity, which would not have otherwise occurred."

Noting the poignant timing of the announcement, right after International Women's Day (March 8), Grand Challenges Canada's Chief Executive Officer Dr. Peter Singer said: "This life-saving device is the 'double-double' of global health it leverages both the global ubiquity of mobile phones and the know-how and financial resources of the private sector. We hope this innovation will move swiftly from its invention in a Vancouver lab to villages around the globe, creating jobs in Canada while saving lives around the world."

Grand Challenges Canada's $1 million contribution comes from funds available under a new $10 million strategic partnership agreement announced today between Grand Challenges Canada and DFATD. The new funds will accelerate the scale up of highly promising health innovations in developing countries. It will also enable innovators to access funding, technical and business support and other resources to accelerate their transition to scale.

Said Tom Walker, President and CEO of LGTmedical: "Thanks to this private and public investment, we can produce a tool with the potential to save the lives of women and children in remote, resource-poor communities around the world. We encourage other impact investors to join us in this landmark venture."

"This innovation by LGTmedical is a great example of how we stimulate bold ideas with big impact in global health while mobilizing private sector partners," said Grand Challenges Canada's Chairman Joseph L. Rotman." Tackling global health while creating jobs is the best of both worlds."

After initial funding from the Bill & Melinda Gates Foundation, the innovation was subsequently awarded a seed grant in 2011 by Saving Lives at Birth, a partnership between Grand Challenges Canada (GCC), the U.S. Agency for International Development (USAID), the U.K. Department for International Development (DFID), the Governmen
'/>"/>

Contact: Terry Collins
tc@tca.tc
416-538-8712

Lode Roels
lode.roels@grandchallenges.ca
647-328-2021
Grand Challenges Canada

Tom Walker
tom.walker@lgtmedical.com
778-968-8582
LGTmedical


Source:Eurekalert  

Page: 1 2 3 4

Related medicine news :

1. Smartphone app aids college-age women in abusive relationships
2. RF Safe Launches Smartphone Flip Cases for Apple iPhone to Shield Cell Phone Radiation
3. RF Safe Launches Samsung Smartphone Flip Cases To Shield Cell Phone Radiation
4. Proliferation of Smartphones Drives the Market for Mobile Medical Apps, According to a New Trend Report Published by Global Industry Analysts, Inc.
5. RF Safe Cell Phone Radiation Shield, Ferrite Bead and Air-tube Headsets Reduce Smartphone Radiation Risk
6. After Christmas Sale at RF Safe on Air-Tube Headsets That Prevent Radiation Hazards for Kids That Got a New Smartphone for Christmas
7. New tech lets cholesterol-tracking smartphone users take lifesaving selfies
8. TIRR Memorial Hermann Uses Smartphones to Reduce Noise from Overhead Paging
9. Cyber Monday 2013 Smartphone, Tablet Deals – iPad Mini, Kindle, iPad Air, Nexus, Galaxy S4, Iphone 5 as Recommended by Daily News Deals
10. Smartphone apps lack proven strategies to help smokers quit
11. PriceAngels.com Announces Great Discounts On Its i9500 S4 Smartphone
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Smartphone app reads blood oxygen levels to hospital standards, advances to global obstetrics tests
(Date:10/22/2014)... October 22, 2014 On October 22, ... featuring skin diseases both fictional and real. The ... a nonprofit organization committed to advocacy and philanthropy in ... will take the opportunity to impart truth and clarity ... , There are many misconceptions about Morgellons Disease ...
(Date:10/22/2014)... Arbor, MI (PRWEB) October 22, 2014 ... of Schools of Allied Health Professions (ASAHP) Conference on ... Founder and CEO will participate in a panel discussion ... and Practice. , Isabel Healthcare provides a diagnostic decision ... in improving the diagnosis skills of students and clinical ...
(Date:10/22/2014)... Amy Norton HealthDay Reporter ... remain riveted on the three Ebola cases in Dallas. But, ... health threat to Americans. President Barack Obama on Friday ... the virus, which has infected two Dallas nurses who cared ... at Texas Health Presbyterian Hospital. But the U.S. cases ...
(Date:10/22/2014)... 22, 2014 Shriners Hospitals for Children® ... change the current location of Shriners Hospitals for Children ... across from the University of Kentucky Albert B. Chandler ... care center, owned and operated by Shriners Hospitals for ... of children and their families well into the future. ...
(Date:10/22/2014)... Los Angeles, California (PRWEB) October 22, 2014 ... Recovery 2.0: Move Beyond Addiction and Upgrade Your Life (Paperback; ... the field of Yoga & Recovery. This book is ... and thrive in a life of recovery. , Recovery ... of the 12 Steps; Recovery 2.0 is a guide for ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3
... , FRIDAY, Nov. 11 (HealthDay News) -- Certain types ... smokers who are generally anxious, according to a new study. ... to tune out anti-smoking videos that warn how smoking can ... harm others. "If you look at health messages, there ...
... Experts from The Neuroscience Institute at NYU Langone Medical ... discussions at the Society for Neuroscience 41st Annual Meeting ... meeting presents an opportunity for leading scientists from around ... for treating diseases and conditions of the brain," said ...
... Researchers at the University of Liverpool and the universities ... that cases of severe pneumonia among young children are ... cooking stoves. The research, published in the ... smoke from open fires and dirty cooking stoves, the ...
... scientists have developed a new technique using stem cells, ... disease. The technique could be developed for application in ... Thompson lead the research from the Florey Neuroscience Institutes ... the newly established Stem Cells Australia collaboration being launched ...
... THURSDAY, Nov. 10 (HealthDay News) -- Despite the known dangers ... but almost 70 percent want to quit, a new government ... Tim McAfee, director of the Office on Smoking and Health ... during a noon press conference Thursday. There was a ...
... (HealthDay News) -- Eating a high-fiber diet may reduce your ... cereal and whole grains, according to a new review. ... a total of nearly 2 million people. Compared with the ... increase in intake of total dietary fiber and cereal fiber ...
Cached Medicine News:Health News:Negative Anti-Smoking Ads Turn Off Anxious Viewers 2Health News:Woodsmoke from cooking fires linked to pneumonia 2Health News:Stem cell research hopes to repair brain damage of Parkinson's disease 2Health News:Stem cell research hopes to repair brain damage of Parkinson's disease 3Health News:Most Smokers Want to Quit, CDC Report Finds 2Health News:Most Smokers Want to Quit, CDC Report Finds 3Health News:Most Smokers Want to Quit, CDC Report Finds 4Health News:High-Fiber Diet May Help Thwart Colon Cancer 2
(Date:10/22/2014)... Oct. 22, 2014 WHEN: Wednesday, October 29, ... registration available at: http://bit.ly/1yStiU9 SPEAKERS: ... and Visionary Innovation Research Group Senior Research ... self-assembling materials, nanobots and flexible electronics are ... transform our lives in the coming decades. ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
(Date:10/20/2014)...  Luoxis Diagnostics, Inc., a subsidiary of Ampio ... its academic collaborators will present several peer-reviewed posters ... novel RedoxSYS Diagnostic System, a first-in-class platform that ... response to injury or illness.  A poster demonstrating ... marker will be presented by Christopher V. ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... A of Trial Assessing Regimen of ... TUSTIN, Calif., Oct. 7 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... for the treatment of cancer and,hepatitis C virus (HCV) ... first stage of a Phase II trial of bavituximab ...
... TOKYO and CHIPPENHAM, England, October 7 ,Sosei ... and Vectura,Group plc ("Vectura"; LSE: VEC), announce ... efficacy, safety and tolerability of NVA237 presented ... Society (ERS) in Berlin,Germany. The new data ...
Cached Medicine Technology:Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5
... Peel PRESTIGE system was designed with advanced ... of the most demanding skin care practice. ... the Parisian Peel PRESTIGE machine is designed ... to offer maximum versatility and full abrasion ...
... a leading provider of immunofluorescence assays, with ... that includes kits for autoimmune diseases, infectious ... conjugates and components. Our Impact IFA Test ... substrates and kit sizes to choose from. ...
Latex agglutination inhibition slide test for the qualitative detection of hCG in urine....
Test for the quantitative determination of antideoxyribonuclease-B (ADNase-B) in serum....
Medicine Products: